James O. Armitage, MD Dr. Armitage is globally recognized as a leading expert on non-Hodgkin lymphoma, and has played a critical role in advancing bone marrow transplantation. He developed and directed the bone marrow transplant programs at the University of Iowa and later at the University of Nebraska, where he also served as vice chair of Internal Medicine, chief of the Section of Oncology and Hematology, chair of the Department of Internal Medicine, and dean of the College of Medicine. Read More
Jordan Berlin, MD Dr. Berlin is the Ingram Professor of Cancer Research and Professor of Medicine at the Vanderbilt-Ingram Cancer Center. In addition, he is the clinical director of the GI oncology program and the director of the phase 1 research program. Read More
Stephen Caplan, MD Dr. Caplan is Associate Professor of Medicine, Director, Division of Hematology-Oncology, Sir Mortimer B. Davis-Jewish General Hospital, and Acting Director of the Division of Hematology at McGill University. Read More
David Cohn, MD Dr. Cohn is Professor of Gynecologic Oncology, director of the division of gynecologic oncology, director of gynecologic cancer research, and director of the gynecologic oncology fellowship program at The Ohio State University. Dr. Cohn's interests include investigation of comparative effectiveness and cost-effective treatments for gynecologic cancers. Read More
Mario Eisenberger, MD Dr. Eisenberger began his career in private practice as a medical oncologist and hematologist in 1978. He subsequently served as senior investigator for the Cancer Therapy Evaluation Program of the National Cancer Institute and Chief of Oncology at the Baltimore Veteran's Administration Hospital. Also, he has held faculty appointments in oncology and urology at the University of Miami and the University of Maryland. Read More
Jonathan I. Epstein, MD Dr. Epstein was in the Phi Beta Kappa Society and graduated Summa Cum Laude from college at Boston University. Also, he was in the Alpha Omega Alpha Society at Boston University Medical School. Next, Dr. Epstein completed a pathology residency at Johns Hopkins Hospital and a pathology fellowship at Memorial Sloan-Kettering Cancer Center. Read More
Jay Harris, MD Dr. Harris is a Professor of Radiation Oncology at Harvard Medical School. He is a highly-respected, international expert on breast cancer. His initial interest in breast cancer research was triggered because his maternal grandmother was diagnosed with the disease. Read More
Marc Lippman, MD Dr. Lippman is a pioneering breast cancer researcher. He is the Chairman of the Department of Medicine and Deputy Director of the Sylvester Comprehensive Cancer Center at the University of Miami. He is the former head of the Medical Breast Cancer section and senior investigator of the National Cancer Institute. Read More
John Lister, MD Dr. Lister is Professor of Medicine at Temple University and Chief of Hematology and Oncology at the Western Pennsylvania Hospital. Dr. Lister has devoted his career to the study and treatment of hematologic malignancies. Read More
John C. Ruckdeschel, MD Dr. Ruckdeschel is a leading authority on the diagnosis and management of thoracic malignancies with particular expertise in lung cancer. He received his BSc in Biology from Rensselaer Polytechnic Institute and his MD from Albany Medical College in New York. He trained at Hopkins (Osler Intern), Beth Israel (Resident) and the National Cancer Institute (Fellow). Read More
David Raben, MD Dr. Raben is a Professor in the Department of Radiation Oncology at the University of Colorado. He is nationally recognized regarding his work in targeted therapies and radiation, primarily in GI, head and neck cancer and lung cancer. He currently serves on the ASCO and ASTRO education and program planning committees. Read More
Chaim Shustik, MD Dr. Shustik is Professor of Medicine in the division of Hematology/Oncology at McGill University. He is chairman of the myeloma committee of the National Cancer Institute-Clinical Trials Group, and is the principal investigator of several clinical trials in multiple myeloma. Read More
"I am amazed how OA manages difficult cases with varying existing scientific opinions. They have proven to me that they always have the patients best interest in mind. I personally would like to thank OA in the name of my patient."
Izidore Lossos, MD
University of Miami Sylvester Cancer Center
"I have found that the main focus of Oncology Analytics’ decision-making is always the wellbeing of the patient. I look forward to working with oncology analytics indefinitely. I would not want to work with other organizations because, frankly, they don't have my trust when it comes to having the best interest of the patient as the primary directive rather than cost containment."
Matthew Taub, MD
"Oncology Analytics has proven that evidence-based medicine works in the delivery of efficacious and affordable cancer care"
Otis Brawley, MD
Chief Medical & Scientific Officer, Executive VP
American Cancer Society
"OA is a strong advocate for the patient and for appropriate health care expenditure. The company is founded on the most ethical of principles and interacts with treating physicians in a collegial manner. I wholeheartedly support their mission and their methods."
John Lister, MD
Chief of Hematology & Oncology
Western Pennsylvania Hospital
"Two thirds of men with low risk prostate cancer are over-treated. Oncology Analytics uses the latest Epstein criteria to help urologists to decide which early-stage prostate cancer patients may be appropriate candidates for active surveillance rather than surgery or radiotherapy."
Jonathan Epstein, MD
Johns Hopkins Hospital